NASDAQ:PRTG Portage Biotech (PRTG) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free PRTG Stock Alerts $0.58 +0.05 (+8.33%) (As of 10:59 AM ET) Add Compare Share Share Today's Range$0.55▼$0.6450-Day Range$0.42▼$1.0752-Week Range$0.34▼$4.40Volume12,607 shsAverage Volume64,249 shsMarket Capitalization$10.41 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Portage Biotech alerts: Email Address Portage Biotech MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside1,353.0% Upside$8.50 Price TargetShort InterestHealthy0.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.03) to ($0.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.46 out of 5 stars 3.3 Analyst's Opinion Consensus RatingPortage Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.50, Portage Biotech has a forecasted upside of 1,353.0% from its current price of $0.59.Amount of Analyst CoveragePortage Biotech has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.18% of the float of Portage Biotech has been sold short.Short Interest Ratio / Days to CoverPortage Biotech has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Portage Biotech has recently decreased by 84.63%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPortage Biotech does not currently pay a dividend.Dividend GrowthPortage Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRTG. Previous Next 3.3 News and Social Media Coverage News SentimentPortage Biotech has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Portage Biotech this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Portage Biotech to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Portage Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders42.07% of the stock of Portage Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.36% of the stock of Portage Biotech is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Portage Biotech are expected to grow in the coming year, from ($1.03) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Portage Biotech is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Portage Biotech is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPortage Biotech has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here About Portage Biotech Stock (NASDAQ:PRTG)Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.Read More PRTG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRTG Stock News HeadlinesMarch 26, 2024 | globenewswire.comPortage Biotech Completes Monetization of Intensity Therapeutics (INTS) sharesMarch 11, 2024 | finance.yahoo.comPRTG: Extending the RunwayMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 3, 2024 | morningstar.comPortage Biotech Inc PRTGFebruary 28, 2024 | globenewswire.comPortage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business UpdateJanuary 8, 2024 | realmoney.thestreet.comH.C. Wainwright downgrades Portage Biotech on financing overhangJanuary 8, 2024 | realmoney.thestreet.comPortage Biotech just downgraded at H.C. Wainwright, here's whyJanuary 8, 2024 | finance.yahoo.comPRTG: Bridging I-O: Working in Harmony with CheckpointsMarch 28, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.January 4, 2024 | marketwatch.comPortage Biotech Shares Fall 6% on Job Reductions, Paused Drug Development ProgramJanuary 4, 2024 | markets.businessinsider.comPortage Biotech To Pause INKT Clinical Development; To Evaluate Potential Strategic OptionsJanuary 4, 2024 | msn.comPortage Biotech to halt iNKT drug program, cut workforceJanuary 4, 2024 | finance.yahoo.comPortage Biotech Reports Business and Strategic UpdateNovember 28, 2023 | msn.comPortage Biotech GAAP EPS of -$0.29November 28, 2023 | finance.yahoo.comPortage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business UpdateNovember 6, 2023 | benzinga.comPortage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingNovember 6, 2023 | finance.yahoo.comPortage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingOctober 31, 2023 | msn.comPortage Biotech files to sell 9.63M shares for holdersSeptember 29, 2023 | finance.yahoo.comPortage Biotech Announces $6.0 Million Registered Direct OfferingSeptember 20, 2023 | finance.yahoo.comPortage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare ConferenceSeptember 7, 2023 | markets.businessinsider.comAnalyst Expectations for Portage Biotech's FutureSeptember 5, 2023 | marketwatch.comPortage Biotech in Keytruda Collaboration With MerckSeptember 5, 2023 | finance.yahoo.comPortage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid TumorsSeptember 1, 2023 | msn.comCantor Fitzgerald Reiterates Portage Biotech (PRTG) Overweight RecommendationAugust 30, 2023 | finance.yahoo.comPortage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business UpdateAugust 2, 2023 | msn.comHC Wainwright & Co. Maintains Portage Biotech (PRTG) Buy RecommendationAugust 2, 2023 | markets.businessinsider.comPortage Biotech Inc (PRTG) Receives a Buy from H.C. WainwrightSee More Headlines Receive PRTG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/28/2024Fiscal Year End3/31/2024Next Earnings (Estimated)7/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Crude petroleum & natural gas Sub-IndustryN/A Current SymbolNASDAQ:PRTG CUSIPN/A CIK1095435 Webwww.portagebiotech.com Phone416-929-1806FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$11.00 Low Stock Price Target$6.00 Potential Upside/Downside+1,474.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($8.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-177.66% Return on Assets-129.14% Debt Debt-to-Equity Ratio0.01 Current Ratio2.78 Quick Ratio2.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.45 per share Price / Book0.12Miscellaneous Outstanding Shares17,800,000Free FloatN/AMarket Cap$9.61 million OptionableOptionable Beta0.96 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Ian B. Walters M.B.A. (Age 55)M.D., CEO & Chairman of Board Comp: $967.65kMr. Allan J. Lee Shaw CPA (Age 60)Chief Financial Officer Comp: $524.08kMr. Steven InnaimoVice President of Project Management & OperationsDr. Robert A. Kramer Ph.D.Chief Scientific OfficerMr. Brian Wiley (Age 56)Chief Business Officer Comp: $220.69kMr. Justin FairchildVice President of DevelopmentMr. Joseph CiavarellaChief Accounting OfficerMore ExecutivesKey CompetitorsChromocell TherapeuticsNYSE:CHROMustang BioNASDAQ:MBIOAeterna ZentarisNASDAQ:AEZSPsyence BiomedicalNASDAQ:PBMTonix PharmaceuticalsNASDAQ:TNXPView All CompetitorsInstitutional OwnershipArmistice Capital LLCSold 92,000 shares on 2/13/2024Ownership: 10.540%PEAK6 Investments LLCBought 51,221 shares on 2/13/2024Ownership: 0.288%View All Institutional Transactions PRTG Stock Analysis - Frequently Asked Questions Should I buy or sell Portage Biotech stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Portage Biotech in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PRTG shares. View PRTG analyst ratings or view top-rated stocks. What is Portage Biotech's stock price target for 2024? 2 analysts have issued twelve-month target prices for Portage Biotech's shares. Their PRTG share price targets range from $6.00 to $11.00. On average, they anticipate the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 1,353.0% from the stock's current price. View analysts price targets for PRTG or view top-rated stocks among Wall Street analysts. How have PRTG shares performed in 2024? Portage Biotech's stock was trading at $1.82 at the start of the year. Since then, PRTG shares have decreased by 67.9% and is now trading at $0.5850. View the best growth stocks for 2024 here. Are investors shorting Portage Biotech? Portage Biotech saw a drop in short interest in March. As of March 15th, there was short interest totaling 15,400 shares, a drop of 84.6% from the February 29th total of 100,200 shares. Based on an average daily volume of 62,600 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the shares of the stock are sold short. View Portage Biotech's Short Interest. When is Portage Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024. View our PRTG earnings forecast. How were Portage Biotech's earnings last quarter? Portage Biotech Inc. (NASDAQ:PRTG) posted its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.09. Who are Portage Biotech's major shareholders? Portage Biotech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (10.54%), PEAK6 Investments LLC (0.29%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Portage Biotech? Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRTG) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Portage Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.